A new Nature Communications study examines how three peptide‑based natural products, ecumicin analogues, ilamycins and cyclomarins, interfere with the protein quality control machinery of Mycobacterium tuberculosis. Despite binding the same ClpC1 target, each compound triggers distinct proteome‑wide effects, reshaping stress‑response pathways and selectively altering the degradation of key mycobacterial proteins. These mechanistic insights shed light on why ClpC1 remains such a promising target for next‑generation TB therapeutics. 

The authors show that these compounds uniquely modulate chaperone activity, disrupt ClpC1P1P2 substrate handling, and in some cases avoid rescue pathways that typically blunt drug activity, offering valuable clues for better drug design. This is a strong example of the excellent basic science emerging from the broader TB research community and highlights the importance of continued fundamental discovery work.

Read the full paper here.